CureVac (NASDAQ:CVAC) was able to report positive data from Part A of its phase 1 study using its vaccine candidate CVGBM for the treatment of patients with HLA-*02:01-positive patients with newly ...

Moderna MRNA announced that the U.S. government, through the Biomedical Advanced Research and Development Authority (“BARDA”), has awarded the company $590 million to accelerate the development of an ...

Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains driven by rising concerns over U.S. respiratory illnesses. Get Wall ...

CureVac (NASDAQ:CVAC – Free Report) – Stock analysts at Leerink Partnrs upped their FY2025 earnings estimates for shares of CureVac in a note issued to investors on Wednesday, January 22nd.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court. Pfizer, BioNTech win bid to invalidate CureVac's UK COVID ...

Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first American death caused by the H5N1 bird flu. Moderna and Novavax shares ...

Shares in vaccine developers jumped on Tuesday after the US reported its first human death from the H5 strain of bird flu.

Shares of CureVac are trading higher by 13.5% during Monday's session. The stock is gaining following a CDC report highlighting a significant increase in acute respiratory illnesses nationwide.